author-photo

Diego Signorelli

Catholic University of the Sacred Heart

106

Papers

1082

Citations

Citation Trend

Filter By

Papers (74) Sort By

Journal Conference Others

MA08.04 LIPI and outcomes of durvalumab as consolidation therapy after ChRT in patients with locally-advanced NSCLC

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Poziotinib for EGFR and HER2 exon 20 insertion mutation in advanced NSCLC: Results from the expanded access program.

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (8)
First Case Report of Pregnancy on Alectinib in a Woman With Metastatic ALK-Rearranged Lung Cancer: A Case Report

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (1)
Immune-Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer With Uncommon Histology

2021 Clinical Lung Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Upfront pembrolizumab as an effective treatment start in patients with PD-L1 ≥ 50% non-oncogene addicted non-small cell lung cancer and asymptomatic brain metastases: an exploratory analysis.

2021 Clinical & Translational Oncology
Show All
- Source
- Cite
- Save
Citations (1)
184P Bone-targeted agents (BTA) improve survival in advanced non-small cell lung cancer (aNSCLC) patients (pts) with high bone tumor burden (HBTB) treated with PD-(L)-1 inhibitors (ICIs)

2021 Journal of Thoracic Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Tocilizumab for the treatment of immune-related adverse events: a systematic literature review and a multicentre case series.

2021 European Journal of Internal Medicine
Show All
- Source
- Cite
- Save
Citations (1)
Smoking status during first‐line immunotherapy and chemotherapy in NSCLC patients: A case–control matched analysis from a large multicenter study

2021 Thoracic Cancer
Show All
- Source
- Cite
- Save
Citations (9)
Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy.

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (11)
Immunotherapy in advanced Non-Small Cell Lung Cancer patients with poor performance status: The role of clinical-pathological variables and inflammatory biomarkers.

2021 Lung Cancer
Show All
- Source
- Cite
- Save
Citations (3)